Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT03178851
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇿🇦Cancercare, Port Elizabeth, South Africa
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT03174795
- Locations
- 🇺🇸
eStudySite, La Mesa, California, United States
🇭🇺Semmelweis University, First Dept of Medicine, Budapest, Hungary
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT03170284
- Locations
- 🇭🇺
Szent Imre Hospital; Dept. of Oncology, Budapest, Hungary
🇭🇺Fejér Megyei Szent György Kórház; Pulmonary Medicine, Szekesfehervar, Hungary
🇭🇺Debrecen Uni Medical School; Dept of Pulmonary Medicine, Debrecen, Hungary
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Hemoglobinuria, Nocturnal
- Interventions
- Drug: CrovalimabDrug: Placebo
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT03157635
- Locations
- 🇩🇪
Elblandklinikum Riesa; Klinik fuer Haematologie Onkologie und Gastroenterologie, Riesa, Germany
🇫🇷Institut hematologie Centre Hayem CHU paris Saint-Louis Lariboisiere F Widal Hopital St Louis, Paris, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre Benite, France
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 340
- Registration Number
- NCT03155347
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳Peking University First Hospital, Beijing City, China
🇨🇳The First Affilliated Hospital of Kunming Medical College, Kunming, China
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT03155009
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Hopital Augustin Morvan; Oncologie Thoracique, Brest, France
🇫🇷Hopital Jean Minjoz; Pneumologie, Besancon, France
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT03153163
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai, China
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 382
- Registration Number
- NCT03148418
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Angeles Clinic & Rsch Inst, Los Angeles, California, United States
🇺🇸Northwestern University; Robert H. Lurie Comp Can Ctr, Chicago, Illinois, United States
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03139513
- Locations
- 🇫🇷
CH Metropole de Savoie, CHAMBERY Cedex, France
🇫🇷Hopital Louis Pasteur; Sce Dermatologie, Colmar, France
🇫🇷Hopital Cochin; Dermatologie, Paris, France
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Follicular LymphomaLymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT03135262
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia